Johnson & Johnson is paying $785 million upfront to partner with Sail Biomedicines, including a $465 million equity investment, to advance in vivo CAR-T therapies for immune-mediated diseases. J&J has secured an exclusive option to acquire Sail for an additional $2.58 billion, making the potential total deal value around $3.5 billion if the option is exercised. The collaboration centers on Sail’s lead in vivo CAR-T program, SAIL-0839, which targets CD4+ and CD8+ T cells using an AI-driven, circular ’endless RNA’ platform delivered via targeted nanoparticles, aiming at an immune system reset in autoimmune diseases. Sources: J&J pays Sail $785M, securing option on in vivo CAR-T ... Key takeaways J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy J&J Strikes $3.51 Bln Deal With Sail To Develop In-Vivo CAR-T Therapies For Immune Diseases Johnson & Johnson gets...
- Get link
- X
- Other Apps